Merck KGaA Pfizer\'s Bavencio fails to hit main goals of platinumresistant refractory ovarian cancer study httpswww.firstwordpharma.comnode1605497Â

Merck KGaA, Pfizer's Bavencio fails to hit main goals of platinum-resistant, refractory ovarian cancer study https://www.firstwordpharma.com/node/1605497 

07:31 EST 19 Nov 2018 | FirstWord Pharma

Merck KGaA, Pfizer's Bavencio fails to hit main goals of platinum-resistant, refractory ovarian cancer study https://www.firstwordpharma.com/node/1605497 

More From BioPortfolio on "Merck KGaA, Pfizer's Bavencio fails to hit main goals of platinum-resistant, refractory ovarian cancer study https://www.firstwordpharma.com/node/1605497 "